Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) CEO Sath Shukla sold 17,641 shares of Spero Therapeutics stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.31, for a total transaction of $23,109.71. Following the sale, the chief executive officer now owns 1,143,566 shares of the company’s stock, valued at approximately $1,498,071.46. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Sath Shukla also recently made the following trade(s):
- On Friday, August 2nd, Sath Shukla sold 14,800 shares of Spero Therapeutics stock. The shares were sold at an average price of $1.32, for a total transaction of $19,536.00.
Spero Therapeutics Price Performance
Shares of Spero Therapeutics stock traded down $0.07 during trading hours on Tuesday, hitting $1.27. The company’s stock had a trading volume of 323,154 shares, compared to its average volume of 222,742. The company has a market capitalization of $68.57 million, a PE ratio of 2.95 and a beta of 0.63. The stock has a 50 day moving average of $1.38 and a 200 day moving average of $1.51. Spero Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $1.89.
Institutional Investors Weigh In On Spero Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC acquired a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $1,570,000. Acadian Asset Management LLC grew its holdings in shares of Spero Therapeutics by 121.8% during the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares in the last quarter. Virtu Financial LLC acquired a new stake in Spero Therapeutics in the 1st quarter valued at approximately $31,000. Murchinson Ltd. raised its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after buying an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after acquiring an additional 9,675 shares in the last quarter. 25.60% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research firms recently commented on SPRO. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday. Finally, TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday.
Get Our Latest Report on Spero Therapeutics
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
See Also
- Five stocks we like better than Spero Therapeutics
- Using the MarketBeat Stock Split Calculator
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What is the Australian Securities Exchange (ASX)
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What is a Secondary Public Offering? What Investors Need to Know
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.